Cowen Starts Audentes Therapeutics (BOLD) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Wedbush Starts Audentes Therapeutics (BOLD) at Outperform
August 15, 2016 7:14 AM EDTWedbush initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating and a price target of $20.
"BOLDs AAV-based gene therapy programs are targeted to address significant unmet medical need in life-threatening rare diseases. With clinical readouts expected in 2017 from three wholly-owned... More
